Sonata Capital Group’s AbbVie ABBV Stock Holding History

Sonata Capital Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,637	Closed	-$304K	–	121
2025 Q2	$304K	Sell	1,637 -187	-10%	-$34.8K	0.12%	91
2025 Q1	$382K	Hold	1,824	–	–	0.17%	81
2024 Q4	$324K	Hold	1,824	–	–	0.13%	86
2024 Q3	$360K	Sell	1,824 -420	-19%	-$78.4K	0.15%	85
2024 Q2	$385K	Hold	2,244	–	–	0.2%	65
2024 Q1	$409K	Hold	2,244	–	–	0.19%	79
2023 Q4	$348K	Sell	2,244 -250	-10%	-$36.4K	0.17%	80
2023 Q3	$372K	Hold	2,494	–	–	0.2%	77
2023 Q2	$336K	Sell	2,494 -847	-25%	-$124K	0.17%	81
2023 Q1	$532K	Hold	3,341	–	–	0.29%	64
2022 Q4	$540K	Sell	3,341 -1	-0%	-$153	0.3%	64
2022 Q3	$449K	Hold	3,342	–	–	0.25%	69
2022 Q2	$512K	Hold	3,342	–	–	0.27%	66
2022 Q1	$542K	Hold	3,342	–	–	0.24%	69
2021 Q4	$453K	Hold	3,342	–	–	0.19%	79
2021 Q3	$361K	Buy	3,342 +147	+5%	+$16.8K	0.16%	89
2021 Q2	$360K	Hold	3,195	–	–	0.16%	90
2021 Q1	$346K	Sell	3,195 -225	-7%	-$24.1K	0.17%	92
2020 Q4	$366K	Hold	3,420	–	–	0.18%	87
2020 Q3	$300K	Hold	3,420	–	–	0.17%	89
2020 Q2	$336K	Hold	3,420	–	–	0.21%	82
2020 Q1	$261K	Sell	3,420 -250	-7%	-$21.3K	0.2%	89
2019 Q4	$325K	Hold	3,670	–	–	0.2%	88
2019 Q3	$278K	Buy	3,670 +750	+26%	+$51.4K	0.19%	88
2019 Q2	$212K	Sell	2,920 -500	-15%	-$39.3K	0.15%	99
2019 Q1	$276K	Hold	3,420	–	–	0.21%	83
2018 Q4	$315K	Hold	3,420	–	–	0.26%	75
2018 Q3	$323K	Hold	3,420	–	–	0.22%	84
2018 Q2	$317K	Hold	3,420	–	–	0.23%	84
2018 Q1	$324K	Sell	3,420 -100	-3%	-$11K	0.24%	83
2017 Q4	$340K	Sell	3,520 -300	-8%	-$28.3K	0.25%	85
2017 Q3	$339K	Hold	3,820	–	–	0.25%	85
2017 Q2	$277K	Sell	3,820 -950	-20%	-$63.9K	0.21%	89
2017 Q1	$311K	Hold	4,770	–	–	0.23%	85
2016 Q4	$299K	Hold	4,770	–	–	0.23%	84
2016 Q3	$301K	Hold	4,770	–	–	0.24%	80
2016 Q2	$295K	Hold	4,770	–	–	0.25%	78
2016 Q1	$272K	Sell	4,770 -500	-9%	-$27.9K	0.24%	84
2015 Q4	$312K	Hold	5,270	–	–	0.27%	78
2015 Q3	$287K	Buy	5,270 +220	+4%	+$14.3K	0.27%	77
2015 Q2	$339K	Hold	5,050	–	–	0.29%	75
2015 Q1	$296K	Buy	+5,050	New	+$305K	0.26%	77

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sonata Capital Group's ABBV Position: Q3 2025 in Review

Sonata Capital Group sold out of AbbVie (ABBV) in Q3 2025, closing a stake of 1,637 shares — an estimated $304K sold.

Sonata Capital Group first reported a position in ABBV in Q1 2015 and held it in 42 quarters. The position peaked at $542K in Q1 2022. 3,906 funds tracked by Wall St. Rank hold ABBV as of Q3 2025.

Sonata Capital Group reported no remaining AbbVie position as of Q3 2025 after selling out during the quarter.
Sonata Capital Group sold 1,637 AbbVie shares in Q3 2025, an estimated $304K.
Sonata Capital Group first reported a position in AbbVie in Q1 2015 and held it in 42 quarters.
Sonata Capital Group's AbbVie position peaked at $542K in Q1 2022.
3,906 funds tracked by Wall St. Rank held AbbVie as of Q3 2025.

Based on Sonata Capital Group's 13F filing for Q3 2025, filed 12 Nov 2025.